When it comes to stock trading, there is always something worth following when a company promises to have a treatment for cancer. After all, cancer is responsible for close to 600,000 deaths in the United States each year. Heat Biologics Inc. (NASDAQ:HTBX) is a small company which is working on developing specialty therapies which will hopefully boost the immune function in patients suffering from a wide range of cancers.
Keeping in mind that they are both a small company and the fact that they are still just in the clinical phases of working out a treatment, Heat Biologics Inc. (NASDAQ:HTBX) apparently is giving hope to more than just cancer sufferers, as investors have been flocking to this stock seemingly all week.
Shares of Heat Biologics Inc. (NASDAQ:HTBX) are up an astounding 30.37% to $2.49 in afternoon trading today, a price that is still well under the 52-week high of $4.71, yet almost 6-fold the 52-week low of just $0.40. Obviously this is a volatile stock — one which should continue its volatility in the coming weeks and months ahead as the company moves forward with their treatment developments.
Heat Biologics is set to report their topline results from their Phase 1b study which set out to evaluate HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, Opdivo®, which is for the treatment of non-small cell lung cancer. The reporting will take place on December 5 in Vienna. The results of this study could have a large impact on where the stock goes from here. The combination of a positive report in conjunction with a recent announcement that the company has cut their expenses for the third quarter, could mean further stock increases in the near-term. However, a disappointing report could send the stock tumbling.
[Image Source: HeatBio.com]